Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | TRPM8 | Q7Z2W7 | 9/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29627376 | 0.86 | CHRM2 (0.49) | POLBTDP1CHRM2CHRM1CHRM3 | |
| SCHEMBL18190232 | 0.85 | POLB (0.55) | POLBTDP1CHRM2CHRM1CHRM3 | |
| SCHEMBL20211128 | 0.83 | CHRM2 (0.47) | POLBTDP1CHRM2CHRM1CHRM3 | |
| SCHEMBL6121893 | 0.83 | POLB (0.58) | POLBTDP1CHRM2CHRM1CHRM3 | |
| SCHEMBL20211082 | 0.82 | RIPK1 (0.51) | POLBTDP1CHRM2CHRM1CHRM3 | |
| SCHEMBL6122705 | 0.81 | CHRM2 (0.53) | POLBTDP1CHRM2CHRM1CHRM3 | |
| SCHEMBL6122367 | 0.79 | ALDH1A1 (0.50) | POLBTDP1CHRM2CHRM1CHRM3 | |
| SCHEMBL6121476 | 0.79 | POLB (0.59) | POLBTDP1TRPM8ALDH1A1TSHR | |
| SCHEMBL6122454 | 0.79 | RIPK1 (0.48) | POLBTDP1CHRM2CHRM1CHRM3 | |
| SCHEMBL15238590 | 0.79 | POLB (0.46) | POLBTDP1CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11311619-B2 | Integrin activator vaccine compositions | 7 Hills Pharma Inc. and Texas Heart Institute (US) | 2022-04-26 | — | — | US | claimed |
| US-20220001009-A1 | NOVEL COMPOSITIONS INCLUDING A THERAPEUTIC ANTIBODIES AND/OR A CHECKPOINT INHIBITOR AND AN INTEGRIN ACTIVATING COMPOUND | 7 Hills Pharma LLC (US) | 2022-01-06 | — | — | US | claimed |
| US-20210145796-A1 | METHODS FOR ADMINISTERING COMPOSITIONS INCLUDING INTEGRIN AGONISTS HAVING ANTI-TUMOR ACTIVITY | 7 HILLS PHARMA INC. | 2021-05-20 | — | — | US | claimed |
| US-20210023207-A1 | NOVEL INTEGRIN ACTIVATOR VACCINE COMPOSITIONS | 7 Hills Pharma LLC (US) | 2021-01-28 | — | — | US | claimed |
| US-10716849-B2 | Methods of administering novel integrin activator vaccine compositions | 7 Hills Pharma LLC (US) | 2020-07-21 | — | — | US | claimed |
| US-10709781-B2 | Integrin activator checkpoint inhibitor compositions | 7 Hills Pharma LLC (US) | 2020-07-14 | — | — | US | claimed |
| US-10709780-B2 | Integrin activator vaccine compositions | 7 Hills Pharma LLC (US) | 2020-07-14 | — | — | US | claimed |
| US-20200054743-A1 | NOVEL INTEGRIN ACTIVATOR CHECKPOINT INHIBITOR COMPOSITIONS | 7 Hills Pharma LLC (US) | 2020-02-20 | — | — | US | claimed |
| US-10342866-B2 | Compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants | 7 HILLS INTERESTS LLC (US) | 2019-07-09 | — | — | US | claimed |
| US-9512109-B2 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | TEXAS HEART INSTITUTE (US) | 2016-12-06 | — | — | US | claimed |
| EP-3104867-B1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | 7 Hills Pharma LLC (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20190210992-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE (US) | 2019-07-11 | — | — | US | disclosed |
| US-10342866-B2 | Compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants | 7 HILLS INTERESTS LLC (US) | 2019-07-09 | — | — | US | disclosed |
| US-10287264-B2 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | TEXAS HEART INSTITUTE (US) | 2019-05-14 | — | — | US | disclosed |
| EP-3388429-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | Texas Heart Institute (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20150368234-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE | 2015-12-24 | — | — | US | disclosed |
| US-20150291571-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE | 2015-10-15 | — | — | US | disclosed |
| US-20150250883-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | 7 HILLS PHARMA INC. | 2015-09-10 | — | — | US | disclosed |
| EP-2881392-A1 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | Texas Heart Institute (US) | 2015-06-10 | — | — | EP | disclosed |
| EP-2881393-A1 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | Texas Heart Institute (US) | 2015-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311619-B2 | Integrin activator vaccine compositions | ITGAM, ITGA2B, ITGA1 | POLB 3433/4885TDP1 4410/4885CHRM2 1448/4885 |
| US-20200054743-A1 | NOVEL INTEGRIN ACTIVATOR CHECKPOINT INHIBITOR COMPOSITIONS | CD47, ITGA1, ITGA2B | POLB 1392/4885TDP1 3302/4885CHRM2 2293/4885 |
| US-20220001009-A1 | NOVEL COMPOSITIONS INCLUDING A THERAPEUTIC ANTIBODIES AND/OR A CHECKPOINT INHIBITOR AND AN INTEGRIN ACTIVATING COMPOUND | CD47, ITGB1, ITGAM | POLB 3036/4885TDP1 4306/4885CHRM2 3156/4885 |
| US-20190210992-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | POLB 4239/4885TDP1 4768/4885CHRM2 326/4885 |
| US-10709781-B2 | Integrin activator checkpoint inhibitor compositions | CD47, ITGA1, ITGAM | POLB 1327/4885TDP1 3565/4885CHRM2 2479/4885 |
| US-10716849-B2 | Methods of administering novel integrin activator vaccine compositions | ITGAM, ITGA2B, ITGA2 | POLB 2040/4885TDP1 4534/4885CHRM2 977/4885 |
| US-20150250883-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | ITGB7, ITGB1, ITGA1 | POLB 4047/4885TDP1 4803/4885CHRM2 567/4885 |
| US-10287264-B2 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | ITGB7, ITGAL, ITGB1 | POLB 4210/4885TDP1 4738/4885CHRM2 310/4885 |
| US-20150291571-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | POLB 4149/4885TDP1 4720/4885CHRM2 352/4885 |
| US-20150368234-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | POLB 4149/4885TDP1 4720/4885CHRM2 352/4885 |
| US-20210145796-A1 | METHODS FOR ADMINISTERING COMPOSITIONS INCLUDING INTEGRIN AGONISTS HAVING ANTI-TUMOR ACTIVITY | ITGB7, ITGA1, ITGAL | POLB 3578/4885TDP1 4406/4885CHRM2 1401/4885 |
| US-10709780-B2 | Integrin activator vaccine compositions | ITGAM, ITGA2B, ITGA1 | POLB 3356/4885TDP1 4577/4885CHRM2 1770/4885 |
| US-20210023207-A1 | NOVEL INTEGRIN ACTIVATOR VACCINE COMPOSITIONS | ITGA2B, ITGAM, ITGAV | POLB 3658/4885TDP1 4422/4885CHRM2 1658/4885 |
| US-10342866-B2 | Compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants | CD4, ICOS, CD274 | POLB 2152/4885TDP1 3130/4885CHRM2 1976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.